BRAIN and NERVE－神経研究の進歩76巻9号

2024年09月発行

特集 治療可能な認知症としてのアルツハイマー病

アルツハイマー病に対する新たな治療戦略

著者： 富田泰輔¹

所属機関： ¹東京大学大学院薬学系研究科機能病態学教室

ページ範囲：P.1053 - P.1058

文献概要

アルツハイマー病（Alzheimer's disease：AD）患者脳の病理学的特徴である老人斑および神経原線維変化の生化学的解析を嚆矢とした分子病態の理解と，家族性ADの解析に始まる遺伝学的解析が相まって，アミロイドβ（Aβ）の凝集および蓄積がAD発症機構における重要なプロセスの1つであることを示した。凝集Aβに対するレカネマブの成功はその結実とも言える。一方，ADおよび各種タウオパチーの原因分子としてのタウに対する創薬研究が徐々に進みつつある。さらに遺伝学的解析から示唆されたグリア細胞の炎症応答がAD病態の修飾因子であることが明確となり，炎症制御という新たな治療戦略も考えられるようになった。本論においてはこれらADに対する新たな治療戦略について最新の知見をまとめる。

参考文献

1）Self WK, Holtzman DM: Emerging diagnostics and therapeutics for Alzheimer disease. Nat Med 29: 2187-2199, 2023

2）Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, et al: Alzheimer's disease drug development pipeline: 2024. Alzheimers Dement (N Y) 10: e12465, 2024［doi: 10.1002/trc2.12465］

3）De Strooper B, Karran E: New precision medicine avenues to the prevention of Alzheimer's disease from insights into the structure and function of γ-secretases. EMBO J 43: 887-903, 2024

4）Niewoehner J, Bohrmann B, Collin L, Urich E, Sade H, et al: Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 81: 49-60, 2014

5）Kariolis MS, Wells RC, Getz JA, Kwan W, Mahon CS, et al: Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys. Sci Transl Med 12: eaay1359, 2020［doi: 10.1126/scitranslmed.aay1359］

6）Kulic L, Alcaraz F, Thanasopoulou A, Vogt A, Hofmann C, et al: Rapid dose-dependent amyloid plaque depletion with trontinemab, a novel BrainshuttleTM antibody in development for the treatmetn of Alzheimer's disease. 2024　https://medically.roche.com/global/en/neuroscience/adpd-2024/medical-material/ADPD-2024-presentation-kulic-rapid-dose-dependent-amyloid-plaque-pdf.html（最終閲覧日: 2024年6月26日）

7）Congdon EE, Ji C, Tetlow AM, Jiang Y, Sigurdsson EM: Tau-targeting therapies for Alzheimer disease: current status and future directions. Nat Rev Neurol 19: 715-736, 2023

8）Mummery CJ, Börjesson-Hanson A, Blackburn DJ, Vijverberg EGB, De Deyn PP, et al: Tau-targeting antisense oligonucleotide MAPT in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial. Nat Med 29: 1437-1447, 2023

9）Barker SJ, Thayer MB, Kim C, Tatarakis D, Simon M, et al: Targeting transferrin receptor to transport antisense oligonucleotides across the blood-brain barrier. bioRxiv 2023［doi: 10.1101/2023.04.25.538145］

10）Schlepckow K, Morenas-Rodríguez E, Hong S, Haass C: Stimulation of TREM2 with agonistic antibodies-an emerging therapeutic option for Alzheimer's disease. Lancet Neurol 22: 1048-1060, 2023

11）Iguchi A, Takatori S, Kimura S, Muneto H, Wang K, et al: INPP5D modulates TREM2 loss-of-function phenotypes in a β-amyloidosis mouse model. iScience 26: 106375, 2023［doi: 10.1016/j.isci.2023.106375］

12）Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K: Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 541: 163-166, 1991

13）Chen Y, Song S, Parhizkar S, Lord J, Zhu Y, et al: APOE3ch alters microglial response and suppresses Aβ-induced tau seeding and spread. Cell 187: 428-445. e20, 2024

14）Jackson RJ, Hyman BT, Serrano-Pozo A: Multifaceted roles of APOE in Alzheimer disease. Nat Rev Neurol, 2024. Online ahead of print［doi: 10.1038/s41582-024-00988-2］

15）Kidana K, Tatebe T, Ito K, Hara N, Kakita A, et al: Loss of kallikrein-related peptidase 7 exacerbates amyloid pathology in Alzheimer's disease model mice. EMBO Mol Med 10: e8184, 2018［doi: 10.15252/emmm.201708184］

16）Tomizawa I, Nakagawa H, Sohma Y, Kanai M, Hori Y, et al: Photo-oxygenation as a new therapeutic strategy for neurodegenerative proteinopathies by enhancing the clearance of amyloid proteins. Front Aging Neurosci 14: 945017, 2022［doi: 10.3389/fnagi.2022.945017］

17）Ozawa S, Hori Y, Shimizu Y, Taniguchi A, Suzuki T, et al: Photo-oxygenation by a biocompatible catalyst reduces amyloid-β levels in Alzheimer's disease mice. Brain 144: 1884-1897, 2021

18）Nagashima N, Ozawa S, Furuta M, Oi M, Hori Y, et al: Catalytic photooxygenation degrades brain Aβ in vivo. Sci Adv 7: eabc9750, 2021［doi: 10.1126/sciadv.abc9750］

19）Suzuki T, Hori Y, Sawazaki T, Shimizu Y, Nemoto Y, et al: Photo-oxygenation inhibits tau amyloid formation. Chem Commun (Camb) 55: 6165-6168, 2019

20）Nakamura R, Tomizawa I, Iwai A, Ikeda T, Hirayama K, et al: Photo-oxygenation of histidine residue inhibits α-synuclein aggregation. FASEB J 37: e23311, 2023［doi: 10.1096/fj.202301533R］